Table 3.
Echocardiographic and Humoral Assessment After Volume Expansion and Placebo or BNP Treatment
| Normal (n = 20) |
PSD (n = 20) |
PDD (n = 18) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Volume Expansion and Placebo |
Volume Expansion and SQ BNP |
Volume Expansion and Placebo |
Volume Expansion and SQ BNP |
Volume Expansion and Placebo |
Volume Expansion and SQ BNP |
|||||||
| EF, % | 66.9 | 3.1 | 68.0 | 3.6 | 42.4 | 10.7 | 43.2 | 9.7 | 66.6 | 4.7 | 67.3 | 4.4 |
| SV, ml/beat | 93.3 | 13.5 | 85.5 | 13.0 | 99.3 | 18.7 | 95.6 | 21.1 | 105.4 | 26.0 | 102.4 | 25.4 |
| E/e=, medial | 7.2 | 1.3 | 7.2 | 1.5 | 16.7 | 12.7 | 11.9 | 1.3 | 14.7 | 4.3 | 12.2 | 4.7 |
| RVSP, mm Hg | 24.4 | 2.9 | 22.5 | 3.3 | 33.8 | 10.9 | 30.5 | 9.9 | 33.9 | 8.3 | 32.6 | 11.0 |
| BNP, pg/ml | 20 | 15 | 196 | 273* | 109 | 137 | 541 | 757* | 101 | 92 | 663 | 1,550* |
| Plasma cGMP, pmol/ml | 2.3 | 1.5 | 12.8 | 20.7* | 5.5 | 8.3 | 9.6 | 6.5* | 3.4 | 1.3 | 10.4 | 8.5* |
Values are mean SD. Echocardiographic, BNP, and cGMP assessment was performed immediately after volume expansion and placebo or SQ BNP pre-treatment.
*
p < 0.05 compared to volume expansion and placebo as measured by t test for normally distributed continuous variables and the rank-sum test for continuous variables with a skewed distribution.